^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    vadastuximab talirine (SGN-CD33A)

    i
    Other names: SGN-CD33A, humanized mAb against CD33 conjugated to 2 pyrrolobenzodiazepine dimer moieties, SGN CD33A
    Company:
    Pfizer
    Drug class:
    DNA replication inhibitor, CD33-targeted antibody-drug conjugate
    Related drugs:
    4years
    CD33-Targeted Therapies: Beating the Disease or Beaten to Death? (PubMed, J Clin Pharmacol)
    Gemtuzumab ozogamicin was the first and only CD33-directed antibody-drug conjugate to be US Food and Drug Administration approved for AML...Promising new strategies include cellular therapy mechanisms and linker molecules. This is an exciting target that requires a considerable amount of precision to yield clinical benefit.
    Review • Journal
    |
    CD33 (CD33 Molecule)
    |
    Mylotarg (gemtuzumab ozogamicin) • IMGN779 • vadastuximab talirine (SGN-CD33A) • vixtimotamab (AMV564) • AVE9633 • GTB-3550 TRIKE • eluvixtamab (AMG 330)
    over4years
    CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A. (PubMed, J Hematol Oncol)
    We tested whether a single nucleotide polymorphism (SNP) that affects splicing of CD33 predicted response to treatment in adults with acute myeloid leukemia (AML) who received the novel CD33 antibody-drug conjugate SGN-CD33A. This genotype, for the CD33 splice site SNP rs12459419, was not associated with clinical response (30% CR/CRi in both groups), event-free survival, or overall survival.
    Clinical • Journal
    |
    CD33 (CD33 Molecule)
    |
    vadastuximab talirine (SGN-CD33A)